Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA
Shots:
- Formycon and its license partner Klinge Biopharma submitted the BLA for FYB203, a biosimilar candidate for Eylea (aflibercept)
- Eylea targets vascular endothelial growth factor (VEGF) and is indicated for the treatment of neovascular age-related macular degeneration (nAMD) and other severe retinal diseases
- Additionally, six biosimilars are currently being developed by Formycon. The company is also working on the development of COVID-19 drug, FYB207, based on its extensive experience in the development of biopharmaceutical drugs
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon Reports the US FDA Acceptance of BLA for FYB203 (biosimilar, aflibercept) to Treat Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
